8th canadian melanoma conference
research frontiers

Conference Program

February 20-23
Rimrock Resort Hotel
Banff • Alberta • Canada

2014

Conference Overview

OBJECTIVES

- Identify new targets and targeted agents in the treatment of melanoma such as PD-1
- Identify key industry partners who would prioritize the development of products and programs in melanoma management in Canada
- Continue to build the network of basic and clinical investigators in order to promote translational and clinical research across Canada
- Discuss short and long-term research strategies

ACCREDITATION

Royal College of Physicians and Surgeons of Canada

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, and approved by the University of Calgary Office of Continuing Medical Education and Professional Development. Participants can claim up to a maximum of 12 study credits.

PROGRAM PLANNING COMMITTEE

Chair: Michael Smylie, *Medical Oncologist, Cross Cancer Institute; Professor, Division of Medical Oncology, University of Alberta*

Joel Claveau, *Dermatologist, Melanoma and Pigmented Lesions Clinic, Hôpital Hôtel Dieu de Québec*

Scott Ernst, *Head, Division of Medical Oncology, London Regional Cancer Program*

David Hogg, *Professor of Medicine, Departments of Medicine and Medical Biophysics, University of Toronto*

J. Gregory McKinnon, *Professor of Surgery and Oncology, University of Calgary and Tom Baker Cancer Centre*

Teresa Petrella, *Medical Oncologist, Sunnybrook Odette Cancer Centre; Assistant Professor, University of Toronto*

Thomas G. Salopek, *Associate Professor and Divisional Director, Division of Dermatology and Cutaneous Science, University of Alberta*

Alan Spatz, *Professor of Pathology and Oncology, McGill University; Canada Research Chair in Molecular Pathology; Director, Department of Pathology, Jewish General Hospital*

Kate Bailey, *Conference Secretariat, BUKSA Strategic Conference Services*

FOR MORE INFORMATION

Canadian Melanoma Conference Secretariat
BUKSA Strategic Conference Services
Tel: 780.436.0983 ext. 233
Email: melanoma@buksa.com
Fax: 780.437.5984

www.buksa.com/melanoma

SPONSORS

Roche

We Innovate Healthcare

MERCK

NOVARTIS

Bristol-Myers Squibb

Celgene

AMGEN®

PATIENT ADVOCACY GROUPS

CSPA
Canadian Skin Patient Alliance

Melanoma Network of Canada
Sun Safe. Sun Aware.

save your skin FOUNDATION

LA FONDATION sauve ta peau

Schedule at a Glance

THURSDAY, FEBRUARY 20, 2014

6:00 - 8:00 pm	Registration	WILDROSE FOYER
6:00 - 8:00 pm	Opening Reception	WILDROSE FOYER

FRIDAY, FEBRUARY 21, 2014

7:00 - 7:45 am	Breakfast and Registration	WILDROSE A
7:45 - 8:00 am	Conference Opening	WILDROSE B & C
8:00 - 9:30 am	**THEME 1:** Basic Science, Pathology and Epidemiology	WILDROSE B & C
9:30 - 10:00 am	Refreshment Break	WILDROSE FOYER
10:30 - 11:30 am	**THEME 1:** Basic Science, Pathology and Epidemiology	WILDROSE B & C
11:30 am	Boxed Lunch and Free Time	WILDROSE FOYER
11:45 am	Ski Shuttle To Sunshine Village	
5:30 - 6:30 pm	Evening Session	WILDROSE B & C

SATURDAY, FEBRUARY 22, 2014

7:00 - 7:30 am	Breakfast	WILDROSE A
7:30 - 9:15 am	**THEME 2:** Surgery and Dermatology	WILDROSE B & C
9:15 - 9:45 am	Refreshment Break	WILDROSE FOYER
9:45 - 11:45 am	**THEME 2:** Surgery and Dermatology	WILDROSE B & C
11:45 am	Boxed Lunch and Free Time	WILDROSE FOYER
12:00 pm	Ski Shuttle To Sunshine Village	
5:30 - 6:45 pm	Case Study Presentation	WILDROSE B & C
6:45 pm	Dinner	HAWTHORNE

SUNDAY, FEBRUARY 23, 2014

7:00 - 7:45 am	Breakfast	WILDROSE A
7:45 - 9:30 am	**THEME 3:** Immunology and Systemic Therapy	WILDROSE B & C
9:30 - 10:00 am	Refreshment Break	WILDROSE FOYER
10:00 - 11:00 am	**THEME 3:** Immunology and Systemic Therapy	WILDROSE B & C
11:00 - 11:15 am	Conference Closing	WILDROSE B & C
11:15 am	Boxed Lunch to Go	WILDROSE FOYER

Program Subject to change.

Conference Program

THURSDAY, FEBRUARY 20, 2014

6:00 – 8:00 pm **Opening Reception & Registration** WILDROSE FOYER

FRIDAY, FEBRUARY 21, 2014

7:00 – 7:45 am **Breakfast and Registration** WILDROSE A

7:45 – 8:00 am **Conference Opening** WILDROSE B & C
Michael Smylie, *Conference Chair*

1 **THEME 1: Basic Science, Pathology and Epidemiology** WILDROSE B & C
SESSION CO-CHAIRS:
Marcus Butler, *Medical Oncologist, Princess Margaret Hospital, Division of Medical Oncology*
Alan Spatz, *Professor of Pathology and Oncology, McGill University*

8:00 – 8:30 am **Update on the Hereditary Melanoma**
Hensin Tsao, Clinical Director, Melanoma Genetics Program, Massachusetts General Hospital
At the end of this session, participants will be able to:
- Recognize the clinical features of various hereditary melanoma phenotypes
- Identify novel genes that confer susceptibility risk

8:30 – 9:00 am **Pathology Error in the Diagnosis and Staging of Cutaneous Melanoma**
Martin Trotter, *Professor, Department of Pathology and Laboratory Medicine, University of Calgary*
At the end of this session, participants will be able to:
- Describe the decision-making hierarchy used by pathologists
- Understand the challenges faced by pathologists in diagnosis and staging of melanoma
- List the most common types of diagnostic errors and explain why these errors occur
- Appreciate the limitations of conventional microscopy in melanoma diagnosis
- List some strategies for minimizing diagnostic discrepancy and error

9:00 – 9:30 am **Precision Medicine in the Clinic:**
The Utility of Next Generation Sequencing in Metastatic Melanoma
Suzanne Kamel-Reid, *Head of Laboratory Genetics, University Health Network*
At the end of this session, participants will be able to:
- Recognize how next generation sequencing data (NGS) is being utilized in the clinical setting.
- Explain the relevance and usefulness of this data for melanoma diagnosis and therapy.
- Differentiate between the challenges, limitations and successes of this approach for melanoma.

9:30 – 10:00 am **Question and Answer Period / Refreshment Break**

10:00 – 10:30 am **Session Talk To Be Confirmed**

Friday, February 21, 2014 continued

10:30 – 11:00 am

Selected Problems in the Diagnosis of Melanocytic Lesions
***Ray Barnhill**, Professor of Pathology, UCLA*

At the end of this session, participants will be able to:
- Identify selected diagnostic problems in melanoma pathology
- Explain how to address the above problems in their medical practice
- Provide strategies and possible techniques for solving the above problems

11:00 – 11:30 am

SRS for Brain Metastases – No more whole brain radiation
***Arjun Sahgal**, Associate Professor, Sunnybrook Health Sciences Centre*

At the end of this session, participants will be able to:
- Explain the changing approach for brain metastases using SRS
- Identify the toxicities of whole brain radiation
- Discuss the technology needed for SRS

11:30 am — **Boxed Lunch and Free Time**

11:45 am — **Ski Shuttle**

5:30 – 6:30 pm

A Practical Discussion of Current Management of BRAF Mutated Melanoma
***Joel Claveau**, Dermatologist, Hôpital Hôtel-Dieu de Québec*
***Alex Eggermont**, Directeur Général, Gustave Roussy Comprehensive Cancer Center*
***Teresa Petrella**, Medical Oncologist, Sunnybrook Odette Cancer Centre*

An interactive symposium and practical workshop panel that will discuss delegate created questions on surveillance, treatment options and long-term side effects of patients with melanoma.

Evening — **At leisure**

SATURDAY, FEBRUARY 22, 2014

7:00 – 7:30 am — **Breakfast** — WILDROSE A

2 **THEME 2: Surgery and Dermatology** — WILDROSE B & C

SESSION CO-CHAIRS:
***Greg McKinnon**, Professor of Surgery and Oncology, University of Calgary and Tom Baker Cancer Centre*
***Thomas Salopek**, Professor, Division of Dermatology and Cutaneous Science, University of Alberta*

7:30 – 8:00 am

Sentinel Lymph Node Biopsy for Melanoma: Current Guidelines and Their Clinical Application
***Christopher Bichakjian**, Associate Professor, Dermatology, University of Michigan*

At the end of this session, participants will be able to:
- Discuss the most recent practice guidelines regarding the use of sentinel lymph node biopsy for cutaneous melanoma.
- Compare and contrast recommendations from melanoma practice guidelines throughout the world with regard to the use of sentinel lymph node biopsy.
- Apply the most recent data and contemporary experience with sentinel lymph node biopsy for melanoma to clinical practice.

Saturday, February 22, 2014 continued

8:00 – 8:30 am

Melanocytic Lesion Volatility in Patients on BRAF Inhibitors
***Ashfaq Marghoob**, Head, Dermatology Section, Memorial Sloan-Kettering Cancer Center*

At the end of this session, participants will be able to:

- Define the changes that occur in melanocytic lesions in patients on a BRAF-inhibitor.
- Acknowledge the increased risk for developing melanoma in patients on a BRAF-inhibitor.
- Describe the proposed reason for why patients on BRAF-inhibitors develop so many changes in their melanocytic lesions.

8:30 – 8:45 am

A Clinicoepidemiological Study of Pediatric Melanoma in Alberta, Canada, from 1992-2011
***Paul Kuzel,** Resident, University of Alberta*

8:45 – 9:15 am

Management of Pediatric Melanoma and Atypical Melanocytic Neoplasms: A Growing Problem
***Vernon Sondak**, Chair, Department of Cutaneous Oncology, Moffitt Cancer Center*

At the end of this session, participants will be able to:

- Increase awareness of the rising incidence of pediatric melanoma and learn typical patterns of clinical presentation.
- Improve the understanding of the significance of melanoma and atypical melanocytic neoplasms in childhood, as well as the challenges associated with diagnosing melanoma in children.
- Improve the understanding of the role of surgery in defining prognosis and identifying candi dates for adjuvant therapy approaches in pediatric melanoma patients.

9:15 – 9:45 am

Question and Answer Period / Refreshment Break

9:45 – 10:15 am

Sentinel Node: Controversies and MSLT Update
***Mark Faries**, Director, Melanoma Research, John Wayne Cancer Institute*

At the end of this session, participants will be able to:

- Explain the prognostic utility of sentinel lymph node biopsy in thin, intermediate-thickness and thick melanoma.
- Describe factors that can help select patients with thin melanoma for sentinel node biopsy
- Discuss the evidence for a survival impact of early nodal surgery in melanoma

10:15 – 10:45 am

The Future of Melanoma Management
***Charles Balch**, Professor of Surgery, Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center*

At the end of this session, participants will be able to:

- Explain the importance of knowing the natural history and prognostic factors of melanoma in conducting clinical trials
- Describe how to integrate new systemic therapies into a multidisciplinary clinical practice
- Explain the diversity of Stage III melanoma patients and describe how to better integrate multidisciplinary treatments among defined “risk groups” based on evidence from clinical trials

10:45 – 11:45 am

Demystifying Myths in Metastatic Melanoma
***Jeffery Weber**, Senior Member, Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center*
***Mateya E. Trinkaus,** Medical Oncologist, Markham Stouffville Hospital*

At the end of this session, participants will be able to:
- Review recent developments in the management of melanoma
- Involve the multidisciplinary team in the management of patients with metastatic melanoma
- Optimize treatment of metastatic melanoma to maximize long-term overall survival

11:45 am — **Boxed Lunch and Free Time**

12:00 pm — **Ski Shuttle**

5:30 – 6:45 pm

Case Study Presentation
***Joel Claveau**, Dermatologist, Hôpital Hôtel-Dieu de Québec*
***Scott Ernst**, Head, Division of Medical Oncology, London Regional Cancer Program*

6:45 pm — **Dinner**

SUNDAY, FEBRUARY 23, 2014

7:00 – 7:45 am — **Breakfast** — WILDROSE A

3

THEME 3: Immunology and Systemic Therapy — WILDROSE B & C

SESSION CHAIRS:
***Teresa Petrella**, Medical Oncologist, Sunnybrook Odette Cancer Centre*
***Ralph Wong**, Medical Oncology, St. Boniface General Hospital*

7:45 – 8:15 am

Clinical and Biomarker Studies of Nivolumab, a PD-1 Blocking Antibody in Melanoma
***Jeffery Weber**, Senior Member, Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center*

At the end of this session, participants will be able to:
- Contrast the mode of action of PD-1 blocking antibodies with that of CTLA-4 blockade
- Summarize the clinical track record of PD1 and PD-L1 antibodies in mid to late clinical development
- Explain how PD-1/PD-L1 antibodies may be combined with ipilimumab and other biologics and what the track record is of combination trials

8:15 – 9:00 am

Bold Predictions for 2020
***Alex Eggermont**, Directeur Général, Gustave Roussy Comprehensive Cancer Center*

At the end of this session, participants will be able to:
- Describe efficacy and limitations of targeted therapies
- Describe efficacy and limitations of immunotherapy
- Explain the issues to come to a rational approach to choose from various combination strategies

Sunday, February 23, 2014 continued

9:00 – 9:30 am

Grand Unification: The rationale for combining immunotherapy with molecularly targeted therapy

***Ryan Sullivan**, Instructor, Department of Medicine, Harvard Medical School*

At the end of this session, participants will be able to:

- Review preclinical data justifying the combination of BRAF directed therapy and immunotherapy
- Describe the clinical data of BRAFi/immunotherapy combinations
- Review ongoing and future trials of BRAFi/immunotherapy combinations

9:30 – 10:00 am

Question and Answer Period / Refreshment Break

10:00 – 10:30 am

Trouble with Trials

***David Hogg,** Professor of Medicine, Departments of Medicine and Medical Biophysics, University of Toronto*

At the end of this session, participants will be able to:

- Discuss an overview and difficulties of trials in melanoma.
- Identify a snapshot of practical problems in clinical trials.

10:30 – 11:00 am

Adoptive Immunotherapy Canada

***Marcus Butler**, Medical Oncologist, Princess Margaret Hospital, Division of Medical Oncology*

At the end of this session, participants will be able to:

- Review current strategies employing adoptive immunotherapy for cancer.
- Understand potential for long-term clinical benefit.
- Discuss opportunities for combination with other therapies.

11:00 – 11:15 am

Conference Closing

***Michael Smylie**, Medical Oncologist, Cross Cancer Institute*

11:15 am

Boxed Lunch to Go

Speakers

Charles Balch

Professor of Surgery, Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center

Dr. Charles M. Balch has led a distinguished career as a clinical and academic surgical oncologist for the past 35 years, as a leading authority in both melanoma and breast cancer. He has also made significant contributions to the field of burnout and career development, in collaboration with the American College of Surgeons and the Mayo Clinic. He is author of over 700 publications (including 19 major publications on burnout), which have been cited over 20,000 times in the biomedical literature, and has lectured in over 38 different countries in the world and most of the major academic centers in the United States. Dr. Balch is the founding Editor-in-Chief of the Annals of Surgical Oncology, which is recognized as the leading journal in the world in its field, and is also the Editor-in-Chief for Patient Resource Cancer Guides, which distribute over one million cancer guides annually (with 14 different titles) to cancer patients throughout the nation.

Raymond Barnhill

Professor of Pathology, Jonsson Comprehensive Cancer Center, UCLA

Dr. Raymond Barnhill is a Professor of Pathology and Co-Director of Dermatopathology at the University of California, Los Angeles. Dr. Barnhill is the author of numerous original articles, chapters and reviews, and the author, co-author, and editor of four books, including two of the leading textbooks in dermatopathology. He received his M.D. from Duke University School of Medicine in 1976 and M.Sc. from the Oxford University in 1982. Dr. Barnhill is internationally renowned for his many original contributions to the diagnosis and classification of melanocytic lesions/melanoma. Over the past fifteen years, Dr. Barnhill has directed a major initiative to characterize the mechanisms of melanoma and other solid tumor metastasis. He has held major academic leadership appointments at Yale, Harvard, Johns Hopkins, and George Washington Universities.

Christopher Bichakjian

Associate Professor, Dermatology, University of Michigan

Dr. Christopher Bichakjian is an associate professor of Dermatology and Associate Chief of the Division of Cutaneous Surgery and Oncology at the University of Michigan Health System. He received his medical degree from Radboud University in The Netherlands and served his internship at Henry Ford Hospital in Detroit. He completed his dermatology residency with additional specialty residency training in melanoma at the University of Michigan in 2001. He completed additional advanced fellowship training in melanoma and cutaneous surgery (Mohs surgery) and oncology at the U-M Comprehensive Cancer Center. Following his departure from the University of Michigan to private practice in New York City, Dr. Bichakjian was recruited back to the U-M melanoma and cutaneous surgery and oncology faculty in 2004. Dr. Bichakjian has a special interest in Merkel cell carcinoma and serves as the director of the Comprehensive Cancer Center Multidisciplinary Merkel Cell Carcinoma program. Dr. Bichakjian is a member of the National Comprehensive Cancer Network (NCCN) Melanoma Guideline Panel and serves as chair of the NCCN Non-Melanoma Skin Cancer Panel.

Marcus Butler

Division of Medical Oncology, Princess Margaret Hospital

Marcus Butler, MD, is a physician investigator with an interest in the translational development of immune-based therapies for cancer patients. He is a member of the medical oncology staff at Princess Margaret Cancer Centre and is an Assistant Professor at the University of Toronto. He cares for patients with melanoma and gynecologic malignancies and is the director of the Princess Margaret Immune Monitoring Laboratory. His work focuses on the development of immunotherapy trials, which include studies, alone and in combination, of immune checkpoint blocking antibodies, immunomodulators, and adoptive cell transfer.

Joel Claveau

Dermatologist, Melanoma and Pigmented Lesions Clinic, Hôpital Hôtel-Dieu de Québec

Dr. Joël Claveau is a dermatologist, specializing in the diagnosis and treatment of melanoma, and an Associate Professor with the Department of Medicine at Laval University where he completed his Medical Study and Internal Medicine training. He completed his residency in Dermatology at McGill University and subsequently worked at the Melanoma Clinic at the Royal Victoria Hospital in Montreal, Quebec.

He is a diplomat of the American Board of Dermatology and is a member of a number of medical societies including the American Academy of Dermatology and the International Dermoscopy Society. He has received many awards including the Young Dermatologist's Volunteer Award of the Canadian Dermatology Association for his work on the prevention of skin cancers.

Since 1996, Dr. Claveau has been the co-Director of the Melanoma and Skin Cancer Clinic at Le Centre Hospitalier Universitaire de Québec, Hôtel-Dieu de Québec, and consultant in Public Health for the province of Québec. He participated in the publication of more than 15 papers in peer-review journals including work on melanoma, sunscreens and tanning parlours. He is actively involved in a numerous Continuing Medical Education (CME) events.

Alexander Eggermont

Directeur Général, Gustave Roussy Comprehensive Cancer Center

Professor Alexander Eggermont is the Director General of the Cancer Institute Gustave Roussy, Villejuif-Paris, France. He is Professor of Surgical Oncology and Professor of International Networking in Cancer Research at the Erasmus University Medical Centre in Rotterdam. He holds the 'Joseph Maisin Chair in Oncology at the Catholic University of Leuven in Belgium. In 1987 he obtained his PhD on 'Interferon and IFN-Inducers in the Treatment of Cancer' at the Erasmus University Rotterdam and is a former Fellow of the NCI Surgery Branch, NIH, Bethesda, USA.

His clinical specialties include melanoma, sarcoma and regional therapy techniques as well as general drug development and clinical trial methodology. He is a past Chair of the EORTC MG Group and current Chair of the Adjuvant Therapy Committee EORTC Melanoma Group.

Alexander Eggermont continued

His basic research field is in tumor immunology, advanced imaging models and tumor pathophysiology.

Professor Eggermont is the author or co-author of over 600 peer-reviewed publications, book chapters and monographs. More than 30 PhD theses have originated in his clinical and basic laboratory research programs at the Erasmus University MC Rotterdam.

Scott Ernst

Head, Division of Medical Oncology, London Regional Cancer Program

Scott Ernst is a Professor of Medicine at the University of Western Ontario in London Ontario where he has also served as Divisional Head, Medical Oncology for the past 3 years. He graduated from University of Ottawa and completed his postgraduate training in Edmonton Alberta, including the Cross Cancer Institute. He has held faculty positions at the Universities of Calgary, East Carolina and most recently, Miami.

His principle clinical interest has been in the management of GU malignancies and melanoma. His specific research has focused upon new drug development and bone metastases. He has participated in numerous national and international clinical trials and has authored over 50 peer reviewed publications. He is currently an executive member of the NCIC CTG Melanoma Group and is a founding co-chair for the Canadian Melanoma Conference.

Mark Faries

Director, Melanoma Research, John Wayne Cancer Institute

Mark Faries is Director of the Melanoma Research Program at the John Wayne Cancer Institute (JWCI) in Santa Monica, California. He received his undergraduate education at Haverford College and his medical degree from Cornell University. His post-graduate medical education was at the University of Pennsylvania for General Surgery and then at the JWCI for Surgical Oncology. He has been a member of the surgical faculty of JWCI and Yale University and is now Professor of Surgery at JWCI. His research includes evaluation of local and regional surgical and immune therapies for melanoma. He has helped lead the Multicenter Sentinel Lymphadenectomy Trials (I & II); the first of which is now complete.

David Hogg

Professor of Medicine; Attending Physician Princess Margaret Hospital; Site Leader Melanoma Oncology, Departments of Medicine and Medical Biophysics, University of Toronto, Faculty of Medicine

Dr. Hogg received his MD in 1980 from the University of Toronto, followed by training in Internal Medicine and Hematology. He carried out his postdoctoral research training in molecular genetics at the Hospital for Sick Children and the Mount Sinai Hospital in Toronto, and at the National Institutes of Health in Bethesda, MD.

Dr. Hogg is currently a Professor in the Department of Medicine at the University of Toronto, and Attending Physician at the Princess Margaret Hospital. He specializes in treating melanoma and sarcoma and has a particular interest in the genetics of sporadic and familial melanoma. He is currently focusing on melanoma clinical trials with a focus on targeted agents and immunotherapy.

Suzanne Kamel-Reid

Head, Laboratory Genetics; Director, Molecular Diagnostics, The University Health Network, Princess Margaret Hospital

Dr. Kamel-Reid is Professor of Laboratory Medicine and Pathobiology, University of Toronto, Senior Scientist, The Ontario Cancer Institute, Head, Laboratory Genetics and Director, Molecular Diagnostics, The University Health Network. Her service laboratory is one of the largest cancer genetics testing laboratory in Canada and focuses on the diagnosis, prognosis and monitoring of many hematological malignancies as well as solid tumors. She is involved in policy making and regulation of genetic testing in Ontario by being a member of the Ontario Genetics Secretariat Executive, a Co-Chair of the Cancer Care Ontario Molecular Oncology Advisory Committee and a Steering Committee Member for the Ontario Genetics Services Strategy Initiative.

In her research laboratory she has cloned and identified two novel variant fusion genes in Acute Promyelocytic Leukemia and created a mouse model of this disease. She has recently identified a 4 gene panel that can help predict local recurrence in patients with oral carcinoma. Her research program focuses on identifying and understanding the utility of genetic markers of disease progression and prognosis as well as developing novel tests for clinical use. She has been the recipient of peer reviewed grant funding from the NCIC, CIHR, Cancer Research Society, OICR and Leukemia Research Fund and has published over 150 papers and 250 abstracts in the field of genetics.

Ashfaq Marghoob

Head, Hauppauge, Dermatology Section, Memorial Sloan-Kettering Cancer Center

Dr. Ashfaq A. Marghoob is a dermatologist specializing in the diagnosis and treatment of cancers of the skin. He is the director of the Memorial Sloan-Kettering regional skin cancer clinic located in Hauppauge, Long Island. In addition to consulting and treating patients in Hauppauge, he also sees patients at the MSKCC outpatient facility in Manhattan. Dr. Marghoob's belief is that improved efforts in educating physicians and the public regarding the importance of early skin cancer detection will translate into lives saved. Dr. Marghoob continues to be engaged in clinical research and he has published numerous papers on topics related to skin cancer with an emphasis on melanoma, atypical/dysplastic nevi, and congenital melanocytic nevi.

Dr. Marghoob is one of the world's leading authorities on dermoscopy. He continuously explores the importance and significance of the clinical and dermoscopic morphology of lesions. Although his research efforts are primarily focused on discovering ways to improve clinician diagnostic accuracy, he is also involved in research aimed at deciphering the natural biology of nevi and melanoma with a particular interest in nevogenesis and melanomagenesis. Dr. Marghoob frequently lectures on all of the aforementioned topics both nationally and internationally.

Greg McKinnon

Professor of Surgery and Oncology, University of Calgary and Tom Baker Cancer Centre

Dr. Gregory McKinnon is a Professor of Surgery and Oncology at the University of Calgary and Tom Baker Cancer Center. He obtained his MD and completed a residency in general surgery at Dalhousie University. He completed sub-specialty training in surgical oncology at Roswell Park Memorial Institute, Buffalo, N.Y. and the Medical College of Virginia. He was a research fellow, Royal Prince Alfred Hospital and Sydney Melanoma Unit at the University of Sydney. He is the former chair of the Royal College Surgical Oncology Specialty Committee, the former chair, Canadian Association of General Surgeons Oncology Committee and the past president of the Canadian Society of Surgical Oncology. He is also the current head of the Cutaneous Oncology Clinic at the Tom Baker Cancer Center and Chair of the Provincial Cutaneous Oncology Tumor Group of Alberta.

Teresa Petrella

Medical Oncologist, Sunnybrook Odette Cancer Centre

Teresa Petrella is a Medical Oncologist at the Sunnybrook Odette Cancer Centre in Toronto, Canada and an Assistant Professor at the University of Toronto. Dr. Petrella has a BSc in Molecular Biology from the University of Western Ontario and completed her MD from Queen's University. Her Internal Medicine and Medical Oncology training was at McMaster University. She subsequently completed a fellowship in Melanoma and Breast cancer at the Sunnybrook Odette Cancer Centre along with a Masters in Health Research Methodology at McMaster University. She was the recipient of a CIHR/CAMO award for her research in Vaccine therapy in combination with Interferon for melanoma patients.

Dr. Petrella joined the staff at OCC in 2002 and became the Head of the Melanoma Site Group. She also Chairs the Provincial Guidelines Melanoma Disease Site Group, Program in Evidence Based Care. She is currently the Chair of the National Cancer Institute of Canada (NCIC) Melanoma Clinical Trials Group. Her research interests are in melanoma and breast cancer and she is currently the Principal Investigator for several multi-centre trials investigating novel therapies in melanoma.

Arjun Sahgal

Associate Professor of Radiation Oncology and Surgery, University of Toronto; Deputy Chief, Department of Radiation Oncology, Sunnybrook Health Sciences Centre

Dr. Arjun Sahgal is a leader in the field of high precision stereotactic radiation to the brain and spine. After training at the University of Toronto in radiation oncology, he completed a fellowship at the University of California San Francisco in brain and spine radiosurgery with Professor Dr. David Larson. Since then he has been recognized as a national and international clinical expert and research leader in radiosurgery. His main focus is on developing spine stereotactic body radiotherapy (SBRT) as an effective therapy for patients with spinal tumors.

Dr. Sahgal has published numerous peer reviewed papers and book chapters on the subject. He has already published 100 peer reviewed papers including high impact journals like

Arjun Sahgal continued

Journal of Clinical Oncology and Lancet Oncology, editor and writer of several books specific to research on brain and bone metastases, editorial board member for several journals, past-chairman of the International Stereotactic Radiosurgery Society meeting held June 2013, and board member for the Brain Tumour Foundation of Canada and the International Stereotactic Radiosurgery Society. He has been invited internationally to speak at several meetings and to various universities as a visiting professor, and leads several research groups. His further research activities involve integrating MRI into radiotherapy delivery, combining novel pharmacologic therapies with radiosurgery, and MRI-Guided focused ultrasound.

Thomas Salopek

Director of Dermatology, Associate Professor, University of Alberta

Dr. Salopek is a Professor in the Division of Dermatology and Cutaneous Sciences at the University of Alberta, Edmonton, Alberta, Canada. He is the Director of the Multidisciplinary Melanoma Clinic at the University Dermatology Center and the Head of the Provincial Cutaneous Tumor Group (Alberta). He is a graduate of the University of Alberta Medical School and Dermatology Residency Program. In addition to having a special interest in melanoma, he also has an interest in dermatologic surgery, psoriasis and other dermatologic diseases with systemic implications, and cutaneous lymphoma.

Michael Smylie

Senior Medical Oncologist, Cross Cancer Institute; Professor, Department of Oncology, University of Alberta

Dr. Michael Smylie is a Medical Oncologist at the Cross Cancer Institute in Edmonton, Alberta. He holds an academic appointment as a Professor in the Department of Oncology at the University of Alberta. He is the past Site Leader for the Clinical Trials Committee and the past Site Leader of the National Cancer Institute of Canada (NCIC). He is very active in designing and participating in clinical trials in malignant melanoma. His other interests include lung cancer. His major research interest is in targeted therapy and new drug development in metastatic melanoma. He has chaired several National Melanoma Meetings and is the current chair of the Canadian national melanoma meeting in Canada.

Vernon Sondak

Chair, Department of Cutaneous Oncology, Moffitt Cancer Center

Vernon Sondak is Chair of the Department of Cutaneous Oncology and Director of Surgical Education at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. He is also a Professor in the Departments of Oncologic Sciences and Surgery at the University of South Florida Morsani College of Medicine. His research interests include surgical treatment of malignant melanoma in adults and children; surgical treatment of Merkel cell carcinoma, dermatofibrosarcoma protuberans and desmoid tumors; adjuvant therapy of melanoma; and evaluation of vaccine treatments for patients with localized or disseminated melanoma. Dr Sondak has also been a leader in studies of surgical treatment of melanoma and other cutaneous malignancies, particularly in the application of sentinel lymph node biopsy to the

Vernon Sondak continued

staging of melanomas, sarcomas, and nonmelanoma skin cancers. He is actively involved in ongoing analyses to determine which patients with thin melanoma are most likely to benefit from sentinel node biopsy, as well as which patients with sentinel node metastases are most likely to have further metastases identified in other regional lymph nodes. Dr Sondak is the author or coauthor of over 300 articles in peer-reviewed publications, 165 abstracts, and 8 books and 68 book chapters.

Alan Spatz

Professor of Pathology and Oncology, Canadian Research Chair in Molecular Pathology

Dr. Alan Spatz is Director of the Pathology Department at the Jewish General Hospital, and Professor of Pathology and Oncology at McGill University. He holds a Canada Research Chair in Molecular Pathology. Dr. Spatz is Co-Chair of the National Cancer Institute of Canada Melanoma Committee. He served as Chair of the EORTC Melanoma group, and as President of the French division of the International Academy of Pathology. He currently serves as a board member of several international professional organizations and on editorial boards and international strategic committees.

Dr. Spatz leads an international research group on cutaneous melanoma. His current research involves the X chromosome role in metastatic potential and key factors associated with cancer progression. He has authored more than 150 original scientific papers, reports, review articles, and books.

Ryan Sullivan

Massachusetts General Hospital Cancer Center

Dr. Ryan Sullivan is a clinical investigator whose main areas of interest are the development of novel molecular therapeutic agents for malignant melanoma, the translation of promising preclinical findings into early stage clinical trials, and the development of predictive biomarkers for these investigational as well as standard treatment approaches. He currently serves as the Principal Investigator (PI) on a study exploring the utility of a novel assay to measure BRAF in the blood of patients with melanoma and is the national PI of the "IL-2 Select in Melanoma" study, which is investigating predictive biomarkers of benefit to high-dose IL-2 in patients with melanoma.

Dr. Sullivan is board certified in both Medical Oncology and Internal Medicine, and an Attending Physician in the Division of Hematology/Oncology at Massachusetts General Hospital (MGH). At the MGH, he is a member of the Center for Melanoma in the MGH Cancer Center. Also, he has an active role at the Dana Farber Harvard Cancer Center, serving on their Institutional Review Board.

Mateya E. Trinkaus

Medical Oncologist, Markham Stouffville Hospital

Dr. Mateya Trinkaus is a staff medical oncologist at the Markham Stouffville Hospital in Markham, Ontario. She completed her training at the University of Toronto, and thereafter completed a 1 year fellowship at the Peter MacCallum Cancer Centre in Melbourne, Australia gaining further expertise in treating various malignancies including melanoma. Thereafter she completed further training in clinical trial development at the NHMRC in Sydney, Australia. She is completing a Masters in Clinical Trials and hopes to start a clinical trial program in her community hospital.

Martin Trotter

Associate Professor, Departments of Pathology / Oncology, University of Calgary

Dr. Trotter received most of his post-secondary education at the University of British Columbia (BSC - Physiology - 1981; MD 1985, PhD 1990). Following his Anatomic Pathology Residency at UBC, he did a Dermatopathology fellowship for one year in London, U.K., at St. John's Institute of Dermatology. Dr. Trotter is a Diplomat (Dermatopathology) of the Royal College of Pathologists (U.K.). Dr. Trotter began his career as a pathologist at Vancouver General Hospital in 1994, and moved to Calgary in 2000. He was the Division Head, Anatomic Pathology and Cytopathology for Calgary Laboratory Services and the University of Calgary from 2002-2008 and has directed the immunohistochemistry laboratory since 2002. Dr. Trotter is a Professor in the Departments of Pathology and Laboratory Medicine and Department of Oncology at the University of Calgary. His major research interests are in skin cancer, especially melanoma, and in workload/quality assurance issues in laboratory medicine.

Hensin Tsao

Clinical Director, Melanoma Genetics Program, Massachusetts General Hospital (MGH)

Hensin Tsao, M.D. Ph.D., graduated from Brown University with a degree in Biochemistry and English. In 1993, he graduated from the Columbia University College of Physicians and Surgeons with an MD degree and Columbia University Graduate School of Arts of Sciences with a PhD degree in Biophysics/Biochemistry. In 2001, Dr. Tsao joined the Wellman Center for Photomedicine and Department of Dermatology at MGH, where he established the Skin Cancer Genetics Laboratory and the MGH Melanoma Genetics Program. In 2005, he became the Director of the MGH Melanoma and Pigmented Lesion Center, which is the oldest multidisciplinary melanoma unit in the country. Since 2007, Dr. Tsao has been Associate Professor of Dermatology at Harvard Medical School.

Dr. Tsao is the author of over 150 peer-reviewed research articles, reviews, abstracts, textbook chapters and online media texts. He is or has been the Chair of the AAD Melanoma/ Skin Cancer Committee, Chair of the AAD Education Committee, Chair of the AAD Task Force on the ABCDE's of Melanoma and is a Member of the Melanoma Guidelines Committee and

Hensin Tsao continued

others. He is the Editor-in-Chief for Journal Watch/Dermatology, an Associate Editor for the British Journal of Dermatology, Journal of the American Academy of Dermatology, the Journal of Investigative Dermatology and the International Journal of Oncology.

Jeff Weber

Senior Member, Donald A. Adam Comprehensive Melanoma Research Center

Dr. Weber earned his Ph.D. in molecular cell biology from Rockefeller University (New York) in 1979 and received his M.D. from New York University in 1980. He completed his internship and residency in Medicine at the University of California, San Diego, and his fellowship in Medical Oncology at the National Cancer Institute in Bethesda, MD.

His experience includes clinical, research and teaching positions at the University of California, Irvine, and the University of Southern California where he was Chief of Medical Oncology and Associate Director for Clinical Research at the USC/Norris Comprehensive Cancer Center. Coming to Moffitt in 2007, Dr. Weber is a Senior Member, Director of the Donald A. Adam Comprehensive Melanoma Research Center, and Professor and Associate Chair for Medicine in the Department of Oncologic Sciences.

Dr. Weber's research interests are in the field of immunotherapy for cancer. As a translational clinical investigator, Dr. Weber has performed a variety of vaccine trials in melanoma patients and in women with high grade cervical intra epithelial neoplasia. His specific laboratory interests are in the monitoring and characterization of T cell responses in patients with cancer, and the establishment of in vitro models to facilitate the understanding of how immune modulation via abrogating and activating antibodies amplifies adaptive immunity in patients. Clinically, he has held 10 investigator initiated IND over the last decade, and has pursued cutting edge trials recently using gene modified dendritic cells, intranodal injection of plasmid peptide priming and boosting and novel antibodies like CTLA 4 and PD 1 abrogating antibodies. He has been a pioneer in the clinical advancement of antibodies that induce autoimmunity as a surrogate for clinical benefit in cancer, and the management of the autoimmune side effects.

NOTES:

www.buksa.com/melanoma